Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs.
The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy.
The company was formerly known asA. P.
Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014.
Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 13, 24 | -0.02 Increased by +92.26% | -0.09 Increased by +76.78% |
| Mar 12, 24 | -0.07 Increased by +58.82% | -0.16 Increased by +56.25% |
| Nov 14, 23 | -0.17 Increased by +55.26% | -0.29 Increased by +41.38% |
| Aug 14, 23 | -0.35 Increased by +36.36% | -0.23 Decreased by -52.17% |
| May 11, 23 | -0.27 Increased by +57.14% | -0.20 Decreased by -35.00% |
| Mar 23, 23 | -0.17 Increased by +68.52% | -0.28 Increased by +39.29% |
| Nov 8, 22 | -0.38 Increased by +25.49% | -0.38 |
| Aug 9, 22 | -0.55 Increased by +11.29% | -0.50 Decreased by -10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 31.43 M Increased by +18.36% | -25.01 M Increased by +40.36% | Decreased by -79.56% Increased by +49.62% |
| Jun 30, 23 | 31.76 M Increased by +14.95% | -42.06 M Increased by +33.47% | Decreased by -132.42% Increased by +42.13% |
| Mar 31, 23 | 29.61 M Increased by +26.25% | -32.47 M Increased by +49.93% | Decreased by -109.65% Increased by +60.34% |
| Dec 31, 22 | 30.03 M Increased by +45.38% | -27.21 M Increased by +50.21% | Decreased by -90.61% Increased by +65.75% |
| Sep 30, 22 | 26.56 M Increased by +14.32% | -41.93 M Increased by +19.99% | Decreased by -157.90% Increased by +30.01% |
| Jun 30, 22 | 27.63 M Increased by +23.11% | -63.22 M Decreased by -3.61% | Decreased by -228.81% Increased by +15.84% |
| Mar 31, 22 | 23.46 M Increased by +17.18% | -64.85 M Decreased by -23.26% | Decreased by -276.48% Decreased by -5.19% |
| Dec 31, 21 | 20.66 M Increased by +0.24% | -54.65 M Increased by +12.26% | Decreased by -264.57% Increased by +12.47% |